Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
was $540 now $319 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback